Cite
HARVARD Citation
Jaeger, H. et al. (2021). Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 8 (11), pp. e679-e689. [Online].